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Background: The neutrophil count has been associated with adverse cardiovascular events after percutaneous coronary
intervention. There are limited data on risk stratification of patients with advanced peripheral vascular disease (PVD)
using white blood cell (WBC) subtypes. This study assessed the association of total and differential WBC counts with
adverse outcome in patients with advanced PVD undergoing percutaneous transluminal angioplasty (PTA).
Methods: In a retrospective cohort study, consecutive de novo procedures were analyzed for patients with Rutherford
category 4 or 5 PVD who underwent successful nonemergency PTA. Cardiovascular risk factors, baseline total and
differential WBC counts, and angiographic data were recorded. Primary outcome was a composite of events of target
vessel revascularization (repeat PTA or vascular bypass operation) or lower limb amputation.
Results: A total of 101 patients were studied. Their mean age was 76  10 years, 54% had diabetes mellitus, 68% were
hypertensive, and 12% had had previous myocardial infarction. We observed 29 events during a median period of 14
months (interquartile range, 4-26). Cox regression analysis found diabetes mellitus (odds ratio [OR], 4.67; 95%
confidence interval [CI], 1.35-16.14; P  .02), Rutherford category 5 (OR, 4.18; 95% CI, 1.06-16.51; P  .04), poor
tibial runoff (OR, 4.42; 95% CI, 1.16-16.82; P  .03), and preprocedural neutrophil count in the third tertile (OR,
10.77; 95% CI, 2.19-52.91; P  .003) were independent predictors of outcome.
Conclusions: The results suggest that the preprocedural neutrophil count could be used in global risk factor assessment of
patients with advanced PVD who are being considered for PTA. The neutrophil count may reflect the burden of
atherosclerosis and tissue damage, and so could identify patients who need more aggressive intervention for advanced
PVD. (J Vasc Surg 2008;48:1504-8.)Several inflammatory markers have been shown to pre-
dict the development of symptomatic atherosclerosis.1-3
Prospective studies have identified the risk of developing
symptomatic peripheral vascular disease (PVD) is associ-
ated with plasma levels of C-reactive protein (CRP).4,5 Risk
stratification of patients with advanced PVD remains diffi-
cult when only traditional cardiovascular risk factors are
used.6 However, inflammatory markers such as CRP, D-
dimer, and fibrinogen have been found to predict the risk of
disease progression in patients with symptomatic PVD.7,8
White blood cell (WBC) count is a simple marker of
inflammation associated with adverse outcomes in patients
with symptomatic coronary artery disease.9 There are lim-
ited data in the literature addressing the prognostic role of
WBC count in the context of advanced PVD. The WBC
count includes several subtypes of cells that are implicated
in the development and progression of atherosclerotic
plaques. The role of monocytes, macrophages, and T-cell
lymphocytes in the formation of atherosclerotic lesions has
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1504been well described, but that of neutrophils is less well
known.10,11 Haumer et al12 found that PVD patients with
neutrophil counts in the upper tertile had a higher risk of
adverse outcome relative to those in the lower tertile. We
set out to identify whether the preprocedural neutrophil
count is associated with an increased risk of an adverse
peripheral vascular outcome in patients with advanced PVD
undergoing percutaneous transluminal angioplasty (PTA).
METHODS
This retrospective cohort study included consecutive
patients with PVD of Rutherford category 4 or 5 who
underwent successful nonemergency PTA within a large
district general hospital from 2002 to 2004. The diagnosis
of PVD was assigned by means of clinical evaluation or
duplex ultrasonography and confirmed by lower limb an-
giography. Patients with a history of surgical lower limb
amputation as a consequence of PVD, or previous surgical
or endovascular lower limb revascularization were excluded
from the study. Patients with a history of autoimmune
disease or on antibiotic therapy were also excluded.
Demographic, cardiovascular risk factors, comorbidi-
ties, and interventional data were recorded by systematic
review of patient hospital records. WBC counts were mea-
sured using flow cytometry by an automated system (Advia
120, Bayer Diagnostics, Tarrytown, NJ). These indices
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scatter signals that were converted into theWBC count and
subtypes. The intra- and inter-assay coefficients of variation
were 3% and 7%. Reference ranges (all expressed as
count per 109 cells/L) were as follows: WBCs, 4.0 to 11;
neutrophils, 1.7 to 7.5; lymphocytes, 1.0 to 4.5; mono-
cytes, 0.2 to 0.8; eosinophils, 0.0 to 0.5, and basophils, 0.0
to 0.1.
A standardized protocol was used for peripheral an-
giography and PTA. Before PTA, patients received 3000
IU of intra-arterial heparin. All interventions were per-
formed by experienced operators, and the PTA technique
used was at the discretion of the treating interventional
radiologists. Primary technical success was defined as a
residual stenosis of 50% at the dilated segment.13
Lesions were categorized as involving the superficial
femoral artery, femoral artery, or popliteal artery, according
to the TransAtlantic InterSociety Consensus (TASC) cate-
gorization of arterial lesions.14 Angiographic documenta-
tion of preprocedural tibial runoff vessels was also available
for all patients. Each of the three tibial vessels was assigned
a score of 0 to 2 according to the extent of luminal disease:
0,50% stenosis; 1, 50% to 99% stenosis; 2, occluded. The
sum of the scores formed the total runoff score of 0 to 6.15
Patients were stratified into two groups of tibial runoff
score 0 to 2 vs 3 to 6.
Patients were routinely followed up in outpatient clinic
at 6 months for clinical re-evaluation. The primary study
end point was the occurrence of a composite of adverse
peripheral vascular events, including target vessel revascu-
larization (repeat PTA or vascular bypass operation) or
surgical limb amputation.
Statistical analysis. Categoric variables are expressed
as frequencies and percentages, and continuous variables
are expressed as mean  standard deviation, unless other-
wise stated. Odds ratios (ORs) are reported with 95%
confidence intervals (CIs). For categoric variables, differ-
ences between groups were assessed using the Pearson
chi-squared test or the two-tailed Fisher exact test. Contin-
Table I. Baseline clinical characteristics according to clinic
Variable
Overall
(N  101) No. (%)a
Age, y 76  10
Male gender 54 (53)
Diabetes 55 (54)
Hypertension 69 (68)
Smoker 27 (27)
Angina 27 (27)
Myocardial infarction 12 (12)
Stroke 15 (15)
Heart failure 17 (17)
Renal impairment 15 (15)
Rutherford category 5 69 (68)
Angiographic data
Tibial run-off score 2 60 (59)
aData for age are expressed as mean  standard deviation.uous variables with a normal distribution were analyzedusing the student t test, and variables with a non-normal
distribution were analyzed using the Wilcoxon rank test.
Cox regression analysis was used to identify indepen-
dent predictors of adverse peripheral vascular outcome.
Variables were entered into the Cox regression model
based on univariate association (P  0.1) with the depen-
dent variable. Kaplan-Meier survival analysis was used to
compare event rate differences between tertiles of neutro-
phil count with the log-rank test. Statistical analysis was
completed using SPSS 14.0 software (SPSS Inc, Chicago,
Ill). For analyses, a value of P  .05 was considered statis-
tically significant.
RESULTS
We studied 101 consecutive patients who were admit-
ted with advanced PVD (Rutherford category 4 in 32,
category 5 in 69), undergoing nonemergency PTA (Table
I). Patients included in the study had balloon angioplasty to
the superficial femoral (n 12), femoral (n 16), popliteal
(n 26), or tibial (n  47) artery. The mean age of the
patients was 76  10 years, 53% were men, 54% had
diabetes mellitus, 68% had hypertension, and 27% were
smokers. Their preprocedural femoral popliteal lesion mor-
phology according to TASC criteria included type A in 33,
type B in 35, type C in 22, and type D in 11. The
preprocedural tibial vessels runoff scores were 0 in 10, 1 in
15, 2 in 16, 3 in 11, 4 in 29, 5 in 9, and 6 in 11.
Total and differential WBC counts were non-normally
distributed. The baseline WBC counts are presented as
median with 25th and 75th percentiles in Table II. During
the median follow-up of 14 months (interquartile range,
4-26 months), 29 adverse events occurred, with 11 repeat
PTA, 9 vascular bypass operations, and 9 below or above
knee amputations. During the study period, 13 patients
died.
Table III summarizes the adverse outcomes for the
cohort per tertile of total and differential WBC subtypes.
There was a significant association between adverse periph-
eral vascular outcome and both preprocedural total WBC
tcome
No event
 59), No. (%)a
Adverse event
(n  42), No. (%)a P
77  10 75  11 .41
25 (42) 29 (69) .01
25 (42) 30 (71) .01
40 (68) 29 (69) .99
14 (24) 13 (31) .50
13 (22) 14 (33) .26
2 (3) 10 (24) .003
10 (17) 5 (12) .58
5 (8) 12 (29) .01
4 (7) 11 (26) .01
35 (59) 34 (81) .03
26 (44) 34 (81) .001al ou
(nand neutrophil counts. The unadjusted hazard ratio for
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tertile preprocedural total WBC count, was OR  3.50
(95% CI, 0.85-14.42; P  .08) for the second tertile and
OR  9.33 (95% CI, 2.34-37.01; P  .001) for the third
tertile. The unadjusted hazard ratio for adverse peripheral
vascular outcome, relative to the first tertile preprocedural
neutrophil count, was OR 1.82 (95% CI, 0.48-6.95; P
.38) for the second tertile and OR  7.65 (95% CI,
2.17-26.94; P  .002) for the third tertile. Figure 1 dem-
onstrates the marked increase in adverse peripheral vascular
outcome for patients with preprocedural neutrophil counts
in the third tertile (log-rank test; P  .001).
Cox regression analysis found diabetes mellitus (OR,
4.67; 95%CI, 1.35-16.14; P .02), Rutherford category 5
(OR, 4.18; 95% CI, 1.06-16.51; P  .04), poor tibial
run-off (OR, 4.42; 95% CI, 1.16-16.82; P  .03), and a
preprocedural neutrophil count in the third tertile (OR,
10.77; 95% CI, 2.19-52.91; P .003) were independently
associated with an adverse peripheral vascular outcome
(Table IV).
DISCUSSION
Preprocedural neutrophil count is an independent pre-
dictor of adverse outcome in the patients with Rutherford
category 4 or 5 PVD undergoing PTA. Univariate analysis
showed the preprocedural WBC count was associated with
adverse outcome. Indeed, studies of patients undergoing
coronary angioplasty have shown that the preprocedural
WBC count is independently associated with both short-
term and long-term adverse outcome.16-18 In our study,
Table II. Baseline preprocedural white blood cell
countsa
Cell type Median (25th–75th percentiles)
Total WBC count 8.3 (6.7-9.9)
Neutrophils 5.7 (4.0-7.1)
Lymphocytes 1.7 (1.2-2.2)
Monocytes 0.4 (0.3-0.6)
Eosinophils 0.2 (0.1-0.3)
Basophils 0.04 (0.02-0.06)
WBC, White blood cell.
aAll cell counts are expressed as count per 109 cells/L.
Table III. Adverse clinical events according to increasing
tertiles of total and differential white blood cells
Cell type
Adverse events for each tertile, No. (%)
P1st tertile 2nd tertile 3rd tertile
Total WBCs 4 (12) 9 (27) 16 (50) .002
Neutrophils 4 (13) 8 (23) 17 (53) .001
Lymphocytes 9 (27) 11 (33) 9 (28) .79
Monocytes 5 (15) 9 (32) 15 (41) .07
Eosinophils 6 (19) 10 (29) 13 (41) .12
Basophils 9 (30) 10 (29) 10 (31) .91
WBC, White blood cell.the neutrophil count in the third tertile appeared to have agreater predictive power of adverse outcome than a history
of diabetes mellitus. Given that traditional risk factors do
not provide a comprehensive prediction model for out-
come in patients with PVD,6 the preprocedural neutrophil
count may provide valuable additional information for as-
sessing outcome in patients with advanced PVD who are
being considered for PTA.
Belch et al19 reported that the baseline WBC count was
associated with a significantly increased risk of lower limb
amputation in patients with critical limb ischemia. Nearly
one-fifth of our patients needed definitive surgical treat-
ment in the form of a vascular bypass operation or surgical
amputation during the follow-up period. It appears that in
addition to established traditional cardiovascular risk, the
preprocedural WBC and neutrophil count could be helpful
in assessing whether advanced PVD can be successfully
treated with PTA. Inflammation has a central role in the
pathophysiology of atherosclerosis.2,20,21 Multiple epide-
Fig. Kaplan-Meier curves for the cumulative probability of ad-
verse outcome by preprocedural neutrophil count tertiles.
Table IV. Cox regression analysis for predictors of
adverse clinical outcomea
Candidate predictors OR (95% CI) P
Diabetes mellitus 4.67 (1.35-16.14) .02
Rutherford category 5 4.18 (1.06-16.51) .04
Tibial run-off score 2 4.42 (1.16-16.82) .03
Pre-procedural neutrophil count
(3rd vs 1st tertile)
10.77 (2.19-52.91) .003
CI, Confidence interval; OR, odds ratio.
aVariables included in the model were sex, diabetes mellitus, prior myocar-
dial infarction, heart failure, renal impairment, Rutherford category, tibial
lesion, tibial runoff score 2, preprocedural neutrophil count tertiles, pre-
procedural WBC cell count tertiles, age, hypertension, smoking status,
angina, and stroke.miologic studies have shown associations between inflam-
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whether markers of inflammation are causal or merely
indicate atherosclerotic burden. Raised inflammatory
markers may occur in response to damaged tissue or vascu-
lar endothelium caused by the severity and extent of ath-
erosclerosis.
In patients with symptomatic PVD, there are conflict-
ing data on the relationship between the WBC count and
the ankle-brachial pressure index (ABPI). The Cardiovas-
cular Health Study examined patients with symptomatic
PVD and found an association between WBC and ABPI
only among women and not men.24 Haumer et al12 found
no significant association between the neutrophil count
and the ABPI or Fontaine stage in patients with intermit-
tent claudication or critical ischemia. However, they did
show that a neutrophil count in the upper tertile was an
independent predictor of major adverse cardiovascular
events. Thus, neutrophil count does not simply reflect
clinical information that can already be gained from mea-
suring ABPI, but is an independent marker for the risk
stratification of patients with advanced PVD.
Circulating neutrophils have been shown to release
reactive species and proteolytic enzymes, which are in-
volved in atherosclerotic plaque disruption.25-27Myeloper-
oxidase released by activated neutrophils weakens the fi-
brous cap of atherosclerotic plaques through activating
metalloproteinases and leads to plaque rupture with conse-
quent vessel occlusion.28 Activated neutrophils can also
aggregate with platelets and adhere to endothelial cells,
which causes plugging of microvessels.29,30 It is through
plaque disruption and microvessel plugging that neutro-
phils could play an active role in the initiation and progres-
sion of tissue ischemia.31
This was an observational study, and as a result we were
unable to adjust for all potentially confounding variables.
Although a single baseline measurement of total and differ-
ential WBC count was used, it is plausible that serial mea-
surement with assays of cellular activation or other inflam-
matory marker such as CRP and interleukin-6 may yield a
different picture. Nevertheless, the simplicity and ready
availability of the WBC and neutrophil count remains an
attractive test for clinicians in a risk assessment model.
Smoking affects WBC count with a positive dose–response
relationship; however, our study was not powered to quan-
tify the effect of smoking.
With regards to medical therapy, statins have a proven
benefit in patients with PVD, in addition to their anti-
inflammatory effect. The use of statins in our patient pop-
ulation was not recorded. We were also not able to report
the ABPI for patients at follow-up because this was not
routinely documented in patient notes. The decision for
further intervention after the index procedure was deter-
mined by clinical symptoms.
CONCLUSIONS
The preprocedural neutrophil count was an indepen-
dent predictor of adverse outcome in patients with ad-
vanced PVD undergoing nonemergency PTA. This simpleand widely available test could be routinely used in clinical
practice to risk stratify patients with advanced PVD being
considered for PTA. Neutrophil count may reflect the
burden of atherosclerosis and tissue damage, and so could
identify patients who needmore aggressive intervention for
advanced PVD.
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